{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:36:07Z","timestamp":1791549367511,"version":"4.3.4"},"reference-count":199,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G0A9Z24N, G075923N"],"award-info":[{"award-number":["G0A9Z24N, G075923N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Fibrosis results from excessive deposition of extracellular matrix (ECM) components following tissue injury. While initially protective, chronic injury drives pathological ECM accumulation, tissue remodeling, and organ dysfunction. In the liver, fibrosis represents a common endpoint of chronic diseases, including metabolic dysfunction\u2013associated steatotic liver disease (MASLD). Macrophages are central players of the fibrotic hepatic niche, modulating inflammatory signals, immune regulation, and tissue repair. Recent advances demonstrate that hepatic macrophages form a heterogeneous and highly dynamic compartment, adopting diverse activation states that extend far beyond the classical M1\/M2 paradigm. Importantly, liver fibrosis is now recognized as a potentially reversible process, with resolution being closely linked to the reprogramming of macrophages towards restorative phenotypes characterized by enhanced efferocytosis, reduced pro-inflammatory signaling, and increased matrix degradation capacity. As a result, efforts to design macrophage-based therapeutic strategies are shifting from non-specific approaches such as inhibition of monocyte recruitment towards approaches that actively promote pro-resolution programs, including targeted\n                    <jats:italic>in situ<\/jats:italic>\n                    reprogramming and more recently cell-based macrophage therapies. In this review, we summarize the hepatic macrophage landscape in the fibrotic liver and discuss current opportunities and challenges in developing macrophage-based anti-fibrotic therapies.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1835489","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:50:34Z","timestamp":1779425434000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeting macrophages in liver fibrosis"],"prefix":"10.3389","volume":"17","author":[{"given":"Lydia","family":"Gonz\u00e1lez del Barrio","sequence":"first","affiliation":[{"name":"Laboratory of Myeloid Cell Biology in Tissue Damage and Inflammation, VIB Center for Inflammation Research","place":["VIB, Ghent, Belgium"]},{"name":"Department of Biomedical Molecular Biology, Faculty of Sciences, Ghent University","place":["Ghent, Belgium"]},{"name":"Global Research, Novo Nordisk A\/S","place":["Bagsvaerd, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Ipsen","sequence":"additional","affiliation":[{"name":"Global Research, Novo Nordisk A\/S","place":["Bagsvaerd, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik R.","family":"Pfister","sequence":"additional","affiliation":[{"name":"Global Research, Novo Nordisk A\/S","place":["Bagsvaerd, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Hancz","sequence":"additional","affiliation":[{"name":"Global Research, Novo Nordisk A\/S","place":["Bagsvaerd, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte L.","family":"Scott","sequence":"additional","affiliation":[{"name":"Laboratory of Myeloid Cell Biology in Tissue Damage and Inflammation, VIB Center for Inflammation Research","place":["VIB, Ghent, Belgium"]},{"name":"Department of Biomedical Molecular Biology, Faculty of Sciences, Ghent University","place":["Ghent, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.matbio.2018.01.019","article-title":"The big five in fibrosis: Macrophages, myofibroblasts, matrix, mechanics, and miscommunication","author":"Pakshir","year":"2018","journal-title":"Matrix Biol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: Therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1300575","article-title":"Fibrosis \u2014 a common pathway to organ injury and failure","volume":"372","author":"Rockey","year":"2015","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188356","article-title":"Fibrosis and cancer: A strained relationship","volume":"1873","author":"Piersma","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1186\/s12967-023-04690-7","article-title":"The impact of fibrotic diseases on global mortality from 1990 to 2019","volume":"21","author":"Mutsaers","year":"2023","journal-title":"J Transl Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.2277","article-title":"Cellular and molecular mechanisms of fibrosis","volume":"214","author":"Wynn","year":"2008","journal-title":"J Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1194988","article-title":"Macrophages and fibrosis: How resident and infiltrating mononuclear phagocytes account for organ injury, regeneration or atrophy","volume":"14","author":"Long","year":"2023","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nature13989","article-title":"Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors","volume":"518","author":"Gomez Perdiguero","year":"2015","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200838855","article-title":"Elie Metchnikoff: Father of natural immunity","volume":"38","author":"Gordon","year":"2008","journal-title":"Eur J Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-012418-012718","article-title":"Diversity, mechanisms, and significance of macrophage plasticity","volume":"15","author":"Locati","year":"2019","journal-title":"Annu Rev Pathol: Mech Dis Annu Rev Pathol Mech Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2705","article-title":"Tissue-resident macrophages","volume":"14","author":"Davies","year":"2013","journal-title":"Nat Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.690813","article-title":"Hepatic macrophage responses in inflammation, a function of plasticity, heterogeneity or both","volume":"12","author":"Zwicker","year":"2021","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.02.015","article-title":"Establishment and maintenance of the macrophage niche","volume":"52","author":"Guilliams","year":"2020","journal-title":"Immunity"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2705","article-title":"Tissue-resident macrophages","volume":"14","author":"Davies","year":"2013","journal-title":"Nat Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"45800","DOI":"10.3389\/fncel.2013.00034","article-title":"Microglia and monocyte-derived macrophages: Functionally distinct populations that act in concert in CNS plasticity and repair","volume":"7","author":"London","year":"2013","journal-title":"Front Cell Neurosci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nature05894","article-title":"Macrophage-specific PPAR\u03b3 controls alternative activation and improves insulin resistance","volume":"447","author":"Odegaard","year":"2007","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1126\/science.1213307","article-title":"A lineage of myeloid cells independent of Myb and hematopoietic stem cells","volume":"335","author":"Schulz","year":"2012","journal-title":"Sci (1979)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.immuni.2013.04.004","article-title":"Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes","volume":"38","author":"Hashimoto","year":"2013","journal-title":"Immunity"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.02.024","article-title":"Tissue-resident macrophage ontogeny and homeostasis","volume":"44","author":"Ginhoux","year":"2016","journal-title":"Immunity"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ni.3341","article-title":"The development and maintenance of resident macrophages","volume":"17","author":"Perdiguero","year":"2016","journal-title":"Nat Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00848-y","article-title":"Tissue-specific macrophages: How they develop and choreograph tissue biology","volume":"23","author":"Mass","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abf7777","article-title":"Three tissue resident macrophage subsets coexist across organs with conserved origins and life cycles","volume":"7","author":"Dick","year":"2022","journal-title":"Sci Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.11.018","article-title":"Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment","volume":"159","author":"Lavin","year":"2014","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032414-112220","article-title":"Macrophages: Development and tissue specialization","volume":"33","author":"Varol","year":"2015","journal-title":"Annu Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10321","article-title":"Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells","volume":"7","author":"Scott","year":"2016","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1165\/RCMB.2013-0086MA","article-title":"Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung","volume":"49","author":"Misharin","year":"2013"},{"key":"B27","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.immuni.2018.10.005","article-title":"Developmental and functional heterogeneity of monocytes","volume":"49","author":"Guilliams","year":"2018","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.12.6166","article-title":"M-1\/M-2 macrophages and the Th1\/Th2 paradigm","volume":"164","author":"Mills","year":"2000","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2004.09.015","article-title":"The chemokine system in diverse forms of macrophage activation and polarization","volume":"25","author":"Mantovani","year":"2004","journal-title":"Trends Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.01.006","article-title":"Transcriptome-based network analysis reveals a spectrum model of human macrophage activation","volume":"40","author":"Xue","year":"2014","journal-title":"Immunity"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1631-3","article-title":"Resolving the fibrotic niche of human liver cirrhosis at single-cell level","volume":"575","author":"Ramachandran","year":"2019","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac113","article-title":"Dynamics of monocyte-derived macrophage diversity in experimental myocardial infarction","volume":"119","author":"Rizzo","year":"2023","journal-title":"Cardiovasc Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41593-020-00789-y","article-title":"Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization","volume":"24","author":"Pombo Antunes","year":"2021","journal-title":"Nat Neurosci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-00849-2","article-title":"Does tissue imprinting restrict macrophage plasticity","volume":"22","author":"Guilliams","year":"2021","journal-title":"Nat Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.immuni.2017.08.008","article-title":"The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases","volume":"47","author":"Krasemann","year":"2017","journal-title":"Immunity"},{"key":"B36","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.immuni.2025.01.002","article-title":"Spatially restricted and ontogenically distinct hepatic macrophages are required for tissue repair","volume":"58","author":"De Ponti","year":"2025","journal-title":"Immunity"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.immuni.2020.04.001","article-title":"Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis","volume":"52","author":"Seidman","year":"2020","journal-title":"Immunity"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","article-title":"A unique microglia type associated with restricting development of Alzheimer\u2019s disease","volume":"169","author":"Keren-Shaul","year":"2017","journal-title":"Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00514","article-title":"From monocytes to M1\/M2 macrophages: Phenotypical vs. functional differentiation","volume":"5","author":"Italiani","year":"2014","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1119964109","article-title":"Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis","volume":"109","author":"Ramachandran","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1038\/s41467-023-37453-5","article-title":"MAIT cell inhibition promotes liver fibrosis regression via macrophage phenotype reprogramming","volume":"14","author":"Mabire","year":"2023","journal-title":"Nat Commun"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J Clin Invest"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-011110-130246","article-title":"Pathogenesis of liver fibrosis","volume":"6","author":"Hernandez-Gea","year":"2011","journal-title":"Annu Rev Pathol: Mech Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nri3623","article-title":"Liver fibrosis and repair: Immune regulation of wound healing in a solid organ","volume":"14","author":"Pellicoro","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: Heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","author":"Stefan","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-024-2722-2","article-title":"Epidemiology of liver diseases: Global disease burden and forecasted research trends","volume":"68","author":"Xiao","year":"2025","journal-title":"Sci China Life Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14103422","article-title":"When metabolic dysfunction-associated steatotic liver disease meets viral hepatitis","volume":"14","author":"Hasanoglu","year":"2025","journal-title":"J Clin Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world introduction and global burden","volume":"70","author":"Asrani","year":"2018","journal-title":"J Hepatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(26)00011-7","article-title":"Global burden of metabolic dysfunction-associated steatotic liver disease, 1990\u20132023, and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2023","volume":"11","author":"Kim","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1611400","DOI":"10.7759\/cureus.69919","article-title":"Resmetirom: a systematic review of the revolutionizing approach to non-alcoholic steatohepatitis treatment focusing on efficacy, safety, cost-effectiveness, and impact on quality of life","volume":"16","author":"Bittla","year":"2024","journal-title":"Cureus"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J Hepatol"},{"key":"B55","first-page":"2","article-title":"Gross and cellular anatomy of the liver","volume-title":"Molecular pathology of liver diseases","author":"Satdarshan","year":"2010"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2017.09.019","article-title":"The liver","volume":"27","author":"Trefts","year":"2017","journal-title":"Curr Biol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00411-3","article-title":"Role of liver sinusoidal endothelial cells in liver diseases","volume":"18","author":"Gracia-Sancho","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/livers1010002","article-title":"The space of Disse: the liver hub in health and disease","volume":"1","author":"Sanz-Garc\u00eda","year":"2021","journal-title":"Livers"},{"key":"B59","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1055\/s-0035-1554915","article-title":"Origin and function of myofibroblasts in the liver","volume":"35","author":"Wells","year":"2015","journal-title":"Semin Liver Dis"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.08.002","article-title":"Liver macrophages in health and disease","volume":"55","author":"Guilliams","year":"2022","journal-title":"Immunity"},{"key":"B61","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.immuni.2019.08.017","article-title":"Stellate cells, hepatocytes, and endothelial cells imprint the Kupffer cell identity on monocytes colonizing the liver macrophage niche","volume":"51","author":"Bonnardel","year":"2019","journal-title":"Immunity"},{"key":"B62","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cell.2021.12.018","article-title":"Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches","volume":"185","author":"Guilliams","year":"2022","journal-title":"Cell"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nature21065","article-title":"Single-cell spatial reconstruction reveals global division of labour in the mammalian liver","volume":"542","author":"Halpern","year":"2017","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41575-019-0134-x","article-title":"Spatial heterogeneity in the mammalian liver","volume":"16","author":"Ben-Moshe","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-031521-024831","article-title":"Spatiotemporal metabolic liver zonation and consequences on pathophysiology","volume":"18","author":"Martini","year":"2023","journal-title":"Annu Rev Pathol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32285","article-title":"Hepatic fibrosis 2022: unmet needs and a blueprint for the future","volume":"75","author":"Friedman","year":"2022","journal-title":"Hepatology"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i23.7260","article-title":"Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: an update","volume":"20","author":"Elpek","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.033","article-title":"Danger signals in liver injury and restoration of homeostasis","volume":"73","author":"Han","year":"2020","journal-title":"J Hepatol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1146\/annurev.immunol.20.083001.084359","article-title":"Innate immune recognition","volume":"20","author":"Janeway","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1172\/JCI88881","article-title":"Liver inflammation and fibrosis","volume":"127","author":"Koyama","year":"2017","journal-title":"J Clin Invest"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.11","article-title":"Liver macrophages in tissue homeostasis and disease","volume":"17","author":"Krenkel","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-021-00373-7","article-title":"Liver regeneration and inflammation: from fundamental science to clinical applications","volume":"22","author":"Campana","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-306842","article-title":"Pathobiology of liver fibrosis: a translational success story","volume":"64","author":"Lee","year":"2015","journal-title":"Gut"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1016\/j.celrep.2019.10.024","article-title":"Single-cell transcriptomics uncovers zonation of function in the mesenchyme during liver fibrosis","volume":"29","author":"Dobie","year":"2019","journal-title":"Cell Rep"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/HEP.510240129","article-title":"Tissue inhibitor of metalloproteinase\u20131 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis","volume":"24","author":"Iredale","year":"1996","journal-title":"Hepatology"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115850","article-title":"Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver","volume":"90","author":"Iredale","year":"1992","journal-title":"J Clin Invest"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1053\/GAST.1996.V110.PM8608892","article-title":"Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver","volume":"110","author":"Benyon","year":"1996","journal-title":"Gastroenterology"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1172\/JCI30542","article-title":"Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ","volume":"117","author":"Iredale","year":"2007","journal-title":"J Clin Invest"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.31083\/FBL27127","article-title":"The role of matrix metalloproteinases in liver function and disease","volume":"30","author":"Mitropoulou","year":"2025","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.02.003","article-title":"Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies","volume":"46","author":"Hemmann","year":"2007","journal-title":"J Hepatol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114472","article-title":"Matrix metalloproteinases induce extracellular matrix degradation through various pathways to alleviate hepatic fibrosis","volume":"161","author":"Shan","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e00360","DOI":"10.1042\/BSR20160107","article-title":"Involvement of matrix metalloproteinases (MMPs) and inflammasome pathway in molecular mechanisms of fibrosis","volume":"36","author":"Robert","year":"2016","journal-title":"Biosci Rep"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1228","article-title":"Morphometry confirms fibrosis regression from sustained virologic response to direct-acting antivirals for hepatitis C","volume":"2","author":"Pan","year":"2018","journal-title":"Hepatol Commun"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1018","article-title":"Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors","volume":"102","author":"Iredale","year":"1998","journal-title":"J Clin Invest"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119671","article-title":"Liver fibrosis resolution: from molecular mechanisms to therapeutic opportunities","volume":"24","author":"Pei","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1042\/CS20060242","article-title":"Liver fibrosis: cellular mechanisms of progression and resolution","volume":"112","author":"Henderson","year":"2007","journal-title":"Clin Sci"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22950","article-title":"Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis","volume":"50","author":"Karlmark","year":"2009","journal-title":"Hepatology"},{"key":"B90","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1172\/jci22675","article-title":"Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair","volume":"115","author":"Duffield","year":"2005","journal-title":"J Clin Invest"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1101\/2025.02.07.636999","article-title":"Mycobacterial infection uncovers plasticity of Kupffer cells","volume":"10","author":"Neuber","year":"2025","journal-title":"bioRxiv"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.07.007","article-title":"Infection history imprints prolonged changes to the epigenome, transcriptome and function of Kupffer cells","volume":"81","author":"Musrati","year":"2024","journal-title":"J Hepatol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1038\/s41467-025-58360-x","article-title":"Kupffer cell and recruited macrophage heterogeneity orchestrate granuloma maturation and hepatic immunity in visceral leishmaniasis","volume":"16","author":"Pessenda","year":"2025","journal-title":"Nat Commun"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq5202","article-title":"Kupffer cell\u2013like syncytia replenish resident macrophage function in the fibrotic liver","volume":"381","author":"Peiseler","year":"2023","journal-title":"Sci (1979)"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1255354","article-title":"Macrophages: master regulators of inflammation and fibrosis","volume":"30","author":"Wynn","year":"2010","journal-title":"Semin Liver Dis"},{"key":"B96","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41423-020-00558-8","article-title":"Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities","volume":"18","author":"Wen","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2308511120","article-title":"The total mass, number, and distribution of immune cells in the human body","volume":"120","author":"Sender","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1002\/j.2040-4603.2013.tb00510.x","article-title":"Kupffer cells in the liver","volume":"3","author":"Dixon","year":"2013","journal-title":"Compr Physiol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S41586-026-10377-Y","article-title":"A spatial atlas of the healthy human liver from live donors","author":"Yakubovsky","year":"2026","journal-title":"Nature"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2006.01342.x","article-title":"Role of Kupffer cells in host defense and liver disease","volume":"26","author":"Bilzer","year":"2006","journal-title":"Liver Int"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.02.013","article-title":"The role of Kupffer cells in hepatic iron and lipid metabolism","volume":"69","author":"Scott","year":"2018","journal-title":"J Hepatol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200050","article-title":"Longevity and replenishment of human liver-resident memory T cells and mononuclear phagocytes","volume":"217","author":"Pallett","year":"2020","journal-title":"J Exp Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.417014","article-title":"Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-\u03b1 production","volume":"287","author":"Tosello-Trampont","year":"2012","journal-title":"J Biol Chem"},{"key":"B104","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.immuni.2020.08.004","article-title":"Osteopontin expression identifies a subset of recruited macrophages distinct from Kupffer cells in the fatty liver","volume":"53","author":"Remmerie","year":"2020","journal-title":"Immunity"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108626","article-title":"Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH","volume":"34","author":"Daemen","year":"2021","journal-title":"Cell Rep"},{"key":"B106","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.immuni.2020.06.003","article-title":"Impaired Kupffer cell self-renewal alters the liver response to lipid overload during non-alcoholic steatohepatitis","volume":"53","author":"Tran","year":"2020","journal-title":"Immunity"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.12703\/P6-13","article-title":"The M1 and M2 paradigm of macrophage activation: Time for reassessment","volume":"6","author":"Martinez","year":"2014","journal-title":"F1000Prime Rep"},{"key":"B108","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.molcel.2019.07.028","article-title":"Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis","volume":"75","author":"Xiong","year":"2019","journal-title":"Mol Cell"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add8945","article-title":"Identification of a broadly fibrogenic macrophage subset induced by type 3 inflammation","volume":"8","author":"Fabre","year":"2023","journal-title":"Sci Immunol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41590-023-01475-4","article-title":"TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer","volume":"24","author":"Park","year":"2023","journal-title":"Nat Immunol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abo2787","article-title":"TREM2 macrophages induced by human lipids drive inflammation in acne lesions","volume":"7","author":"Do","year":"2022","journal-title":"Sci Immunol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add9984","article-title":"Single-cell and spatial transcriptomics identify a macrophage population associated with skeletal muscle fibrosis","volume":"9","author":"Coulis","year":"2023","journal-title":"Sci Adv"},{"key":"B113","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.stem.2019.01.011","article-title":"A subset of TREM2 + dermal macrophages secretes oncostatin M to maintain hair follicle stem cell quiescence and inhibit hair growth","volume":"24","author":"Wang","year":"2019","journal-title":"Cell Stem Cell"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0299","article-title":"Spatial and temporal mapping of breast cancer lung metastases identify TREM2 macrophages as regulators of the metastatic boundary","volume":"13","author":"Yofe","year":"2023","journal-title":"Cancer Discov"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0939-8","article-title":"Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis","volume":"26","author":"Alivernini","year":"2020","journal-title":"Nat Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.01.049","article-title":"TREM2 lipid sensing sustains the microglial response in an Alzheimer\u2019s disease model","volume":"160","author":"Wang","year":"2015","journal-title":"Cell"},{"key":"B117","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/S00018-023-04786-9","article-title":"TREM2 promotes cholesterol uptake and foam cell formation in atherosclerosis","volume":"80","author":"Guo","year":"2023","journal-title":"Cell Mol Life Sci"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/s44161-023-00354-3","article-title":"Trem2 promotes foamy macrophage lipid uptake and survival in atherosclerosis","volume":"2","author":"Patterson","year":"2023","journal-title":"Nat Cardiovasc Res"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.immuni.2022.07.004","article-title":"Dual ontogeny of disease-associated microglia and disease inflammatory macrophages in aging and neurodegeneration","volume":"55","author":"Silvin","year":"2022","journal-title":"Immunity"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/s44161-024-00429-9","article-title":"TREM2 protects from atherosclerosis by limiting necrotic core formation","volume":"3","author":"Piollet","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000557","article-title":"Osteopontin characterizes bile duct-associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis","volume":"79","author":"De Muynck","year":"2024","journal-title":"Hepatology"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2405746121","article-title":"Lipid-associated macrophages\u2019 promotion of fibrosis resolution during MASH regression requires TREM2","volume":"121","author":"Ganguly","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"B123","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.immuni.2022.11.013","article-title":"Prolonged hypernutrition impairs TREM2-dependent efferocytosis to license chronic liver inflammation and NASH development","volume":"56","author":"Wang","year":"2023","journal-title":"Immunity"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.06.004","article-title":"Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH","volume":"77","author":"Hendrikx","year":"2022","journal-title":"J Hepatol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1172\/JCI135197","article-title":"TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis","volume":"131","author":"Hou","year":"2021","journal-title":"J Clin Invest"},{"key":"B126","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.cell.2019.05.054","article-title":"Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner","volume":"178","author":"Jaitin","year":"2019","journal-title":"Cell"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.03.228","article-title":"Macrophage-derived osteopontin (SPP1) protects from nonalcoholic steatohepatitis","volume":"165","author":"Han","year":"2023","journal-title":"Gastroenterology"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.02.015","article-title":"Macrophages in tissue repair, regeneration, and fibrosis","volume":"44","author":"Wynn","year":"2016","journal-title":"Immunity"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.02.026","article-title":"Targeting hepatic macrophages to treat liver diseases","volume":"66","author":"Tacke","year":"2017","journal-title":"J Hepatol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0065251","article-title":"Tumor necrosis factor-\u03b1 promotes cholestasis-induced liver fibrosis in the mouse through tissue inhibitor of metalloproteinase-1 production in hepatic stellate cells","volume":"8","author":"Osawa","year":"2013","journal-title":"PloS One"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1136\/GUTJNL-2011-300304","article-title":"Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury","volume":"61","author":"Baeck","year":"2012","journal-title":"Gut"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3390\/CELLS8111419","article-title":"TGF-\u03b2 in hepatic stellate cell activation and liver fibrogenesis\u2014updated 2019","volume":"8","author":"Dewidar","year":"2019","journal-title":"Cells"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1007\/S00441-011-1246-Y","article-title":"TGF-\u03b2 in progression of liver disease","volume":"347","author":"Dooley","year":"2011","journal-title":"Cell Tissue Res"},{"key":"B134","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1582-4934.2006.tb00292.x","article-title":"Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-\u03b2 as major players and therapeutic targets","volume":"10","author":"Gressner","year":"2006","journal-title":"J Cell Mol Med"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2018.9423","article-title":"Pirfenidone suppresses TGF-\u03b21-induced human intestinal fibroblasts activities by regulating proliferation and apoptosis via the inhibition of the Smad and PI3K\/AKT signaling pathway","volume":"18","author":"Sun","year":"2018","journal-title":"Mol Med Rep"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172592","article-title":"Suppression of TGF-\u03b2 pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro","volume":"12","author":"Stahnke","year":"2017","journal-title":"PloS One"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2019-0328TR","article-title":"Pirfenidone: Molecular mechanisms and potential clinical applications in lung disease","volume":"62","author":"Ruwanpura","year":"2020","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00245-3","article-title":"Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production","volume":"37","author":"Di Sario","year":"2002","journal-title":"J Hepatol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abg9241","article-title":"The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1","volume":"7","author":"Xi","year":"2021","journal-title":"Sci Adv"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70131","article-title":"Noninvasive evaluation of prolonged-release pirfenidone in compensated liver cirrhosis. ODISEA study, a randomised trial","volume":"45","author":"Mu\u00f1oz-Espinosa","year":"2025","journal-title":"Liver Int"},{"key":"B141","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3810","article-title":"Targeting the TGF\u03b2 signalling pathway in disease","volume":"11","author":"Akhurst","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2022.06.007","article-title":"Cell-specific deletion of NLRP3 inflammasome identifies myeloid cells as key drivers of liver inflammation and fibrosis in murine steatohepatitis","volume":"14","author":"Kaufmann","year":"2022","journal-title":"CMGH"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J Hepatol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-39805-z","article-title":"JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders","volume":"13","author":"Ambrus-Aikelin","year":"2023","journal-title":"Sci Rep"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13576","article-title":"First-in-human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC-2394, in healthy volunteers","volume":"16","author":"Tang","year":"2023","journal-title":"Clin Transl Sci"},{"key":"B146","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrd.2018.97","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2006.05.025","article-title":"Migratory fate and differentiation of blood monocyte subsets","volume":"211","author":"Tacke","year":"2006","journal-title":"Immunobiology"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158156","article-title":"Antifibrotic effects of the dual CCR2\/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis","volume":"11","author":"Lefebvre","year":"2016","journal-title":"PloS One"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"B150","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cgh.2023.04.003","article-title":"Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study","volume":"22","author":"Anstee","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.01.038","article-title":"Hepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis","volume":"343","author":"Zhou","year":"2022","journal-title":"J Controlled Release"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.a.36617","article-title":"Modulation of macrophage phenotype via phagocytosis of drug-loaded microparticles","volume":"107","author":"Wofford","year":"2019","journal-title":"J BioMed Mater Res A"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2122310119","article-title":"pH-degradable, bisphosphonate-loaded nanogels attenuate liver fibrosis by repolarization of M2-type macrophages","volume":"119","author":"Kaps","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122545","article-title":"Biomaterial-mediated intracellular control of macrophages for cell therapy in pro-inflammatory and pro-fibrotic conditions","volume":"308","author":"Tylek","year":"2024","journal-title":"Biomaterials"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1021\/nn100262h","article-title":"Rapid uptake of gold nanorods by primary human blood phagocytes and immunomodulatory effects of surface chemistry","volume":"4","author":"Bartneck","year":"2010","journal-title":"ACS Nano"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2012.02.011","article-title":"Drug targeting to the diseased liver","volume":"161","author":"Poelstra","year":"2012","journal-title":"J Controlled Release"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14030669","article-title":"Dually active polycation\/miRNA nanoparticles for the treatment of fibrosis in alcohol-associated liver disease","volume":"14","author":"Zhang","year":"2022","journal-title":"Pharmaceutics"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.10.020","article-title":"Cerium oxide nanoparticles reduce steatosis, portal hypertension and display anti-inflammatory properties in rats with liver fibrosis","volume":"64","author":"Or\u00f3","year":"2016","journal-title":"J Hepatol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.09.013","article-title":"MicroRNA 223 3p negatively regulates the NLRP3 inflammasome in acute and chronic liver injury","volume":"28","author":"Jimenez Calvente","year":"2020","journal-title":"Mol Ther"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2014.10.030","article-title":"Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases","volume":"37","author":"Bartneck","year":"2015","journal-title":"Biomaterials"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.27805","article-title":"Targeting dexamethasone to Kupffer cells: Effects on liver inflammation and fibrosis in rats","volume":"34","author":"Melgert","year":"2001","journal-title":"Hepatology"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.70","article-title":"A guide to immunometabolism for immunologists","volume":"16","author":"O\u2019Neill","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.21037\/atm-21-4602","article-title":"Schisandrin B regulates macrophage polarization and alleviates liver fibrosis via activation of PPAR\u03b3","volume":"9","author":"Chen","year":"2021","journal-title":"Ann Transl Med"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15051452","article-title":"PPAR-\u03b3 agonist GW1929 targeted to macrophages with dendrimer\u2013graphene nanostars reduces liver fibrosis and inflammation","volume":"15","author":"Moreno-Lanceta","year":"2023","journal-title":"Pharmaceutics"},{"key":"B165","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"B167","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13195-025-01759-x","article-title":"Novel fully human high-affinity anti-TREM2 antibody shows efficacy in clinically relevant Alzheimer\u00b4s mouse model","volume":"17","author":"Kraller","year":"2025","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq0095","article-title":"A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimer\u2019s disease","volume":"14","author":"Zhao","year":"2022","journal-title":"Sci Transl Med"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.05.003","article-title":"The physiology, pathology, and potential therapeutic applications of the TREM2 signaling pathway","volume":"181","author":"Deczkowska","year":"2020","journal-title":"Cell"},{"key":"B170","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s13195-024-01599-1","article-title":"Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer\u2019s disease","volume":"16","author":"Long","year":"2024","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.783305","article-title":"Engineered CAR-macrophages as adoptive immunotherapies for solid tumors","volume":"12","author":"Sloas","year":"2021","journal-title":"Front Immunol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24315","article-title":"Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function","volume":"53","author":"Thomas","year":"2011","journal-title":"Hepatology"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aaa2155","article-title":"Analysis of single-cell cytokine secretion reveals a role for paracrine signaling in coordinating macrophage responses to TLR4 stimulation","volume":"8","author":"Xue","year":"2015","journal-title":"Sci Signal"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1007\/s13770-025-00766-1","article-title":"Macrophage paracrine signalling differentially affects fibroblast-induced collagenous tissue remodelling","volume":"23","author":"Brouwer","year":"2025","journal-title":"Tissue Eng Regener Med"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01068-z","article-title":"A new era of macrophage-based cell therapy","volume":"55","author":"Na","year":"2023","journal-title":"Exp Mol Med"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0599-8","article-title":"Safety profile of autologous macrophage therapy for liver cirrhosis","volume":"25","author":"Moroni","year":"2019","journal-title":"Nat Med"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/J.JHEP.2005.01.019","article-title":"Evaluation of the increase in model for end-stage liver disease (DeltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score","volume":"42","author":"Huo","year":"2005","journal-title":"J Hepatol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.11.008","article-title":"The MELD score in patients awaiting liver transplant: Strengths and weaknesses","volume":"54","author":"Bernardi","year":"2011","journal-title":"J Hepatol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.08.009","article-title":"Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium","volume":"74","author":"Sol\u00e0","year":"2021","journal-title":"J Hepatol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1016\/s0168-8278(24)00574-9","article-title":"LBP-007 Beneficial effects of autologous macrophage therapy on clinical outcomes in patients with compensated cirrhosis: extended follow-up data from a randomized controlled phase 2 trial","volume":"80","author":"Brennan","year":"2024","journal-title":"J Hepatol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03406-8","article-title":"Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial","volume":"31","author":"Brennan","year":"2025","journal-title":"Nat Med"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1080\/17460751.2025.2583912","article-title":"Industry updates from the field of stem cell research and regenerative medicine in September 2025","volume":"20","author":"Ilic","year":"2025","journal-title":"Regener Med"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-basl.84","article-title":"P68 An open-label phase 1\/2 multicentre study to evaluate the safety, tolerability and efficacy of RTX001 autologous macrophages in participants with liver cirrhosis who have hepatic decompensation (EMERALD)","volume":"74","author":"Hesketh","year":"2025","journal-title":"Gut"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2015.01.005","article-title":"Large-scale hematopoietic differentiation of human induced pluripotent stem cells provides granulocytes or macrophages for cell replacement therapies","volume":"4","author":"Lachmann","year":"2015","journal-title":"Stem Cell Rep"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071098","article-title":"Efficient, long term production of monocyte-derived macrophages from human pluripotent stem cells under partly-defined and fully-defined conditions","volume":"8","author":"van Wilgenburg","year":"2013","journal-title":"PloS One"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1719452","article-title":"Robust, scalable and xeno-free protocol for differentiating human induced pluripotent stem cells into functional macrophages","volume":"16","author":"De Homdedeu","year":"2026","journal-title":"Front Immunol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07570-7","article-title":"Bioreactor-based mass production of human iPSC-derived macrophages enables immunotherapies against bacterial airway infections","volume":"9","author":"Ackermann","year":"2018","journal-title":"Nat Commun"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101162","article-title":"Strategies for genetically engineering hypoimmunogenic universal pluripotent stem cells","volume":"23","author":"Zhao","year":"2020","journal-title":"iScience"},{"key":"B189","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/ki.2013.341","article-title":"Failed renoprotection by alternatively activated bone marrow macrophages is due to a proliferation-dependent phenotype switch in vivo","volume":"85","author":"Cao","year":"2014","journal-title":"Kidney Int"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114979","article-title":"Biomaterial-assisted macrophage cell therapy for regenerative medicine","volume":"199","author":"Sung","year":"2023","journal-title":"Adv Drug Delivery Rev"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2025.03.004","article-title":"Progress and challenges in developing allogeneic cell therapies","volume":"32","author":"Deuse","year":"2025","journal-title":"Cell Stem Cell"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202256661","article-title":"Cost and availability of novel cell and gene therapies","volume":"24","author":"De Luca","year":"2023","journal-title":"EMBO Rep"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.07.013","article-title":"Learnings from the graveyard of phase 2 and 3 nonalcoholic steatohepatitis trials","volume":"22","author":"Francque","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B194","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J Hepatol"},{"key":"B195","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cgh.2023.04.003","article-title":"Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study","volume":"22","author":"Anstee","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B196","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J Hepatol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.11.024","article-title":"A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis","volume":"72","author":"Harrison","year":"2020","journal-title":"J Hepatol"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterology"},{"key":"B199","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of Belapectin, an inhibitor of Galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1835489\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:50:44Z","timestamp":1779425444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1835489\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":199,"alternative-id":["10.3389\/fimmu.2026.1835489"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1835489","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"article-number":"1835489"}}